Novavax prepares for new BARDA-funded flu studies; raises cash
This article was originally published in Scrip
Executive Summary
Shares of Novavax rose as much as 7.3% on 24 September on word the company was finalizing details of the costs and timelines for its next round of trials testing its quadrivalent seasonal and pandemic influenza vaccine candidates under a contract with the US Biomedical Advanced Research and Development Authority (BARDA) following successful completion of process improvement studies.